Novel leukocyte adsorption device during CPB safe, feasible

20 giờ trước
Stephen Padilla
Stephen PadillaSenior Editor; MIMS
Stephen Padilla
Stephen Padilla Senior Editor; MIMS
Novel leukocyte adsorption device during CPB safe, feasible

A new activated leukocyte adsorption device during cardiopulmonary bypass (CPB) has demonstrated its feasibility and safety in first human study.

“This … pilot study provides preliminary feasibility and safety information on our novel leukocyte adsorption membrane during CPB, perhaps with appropriate modifications to optimize selective binding of activated leukocytes,” said the researchers, noting however that outcomes regarding efficacy cannot be drawn from this study.

The leukocyte adsorption device was combined with the CPB circuit of adults undergoing cardiac surgery. Then, the researchers measured the number of CD11b⁺ neutrophils via flow cytometry from baseline until 48 h following surgery.

The rate of CD11b⁺ neutrophil removal between before and immediately after adsorption served as the primary outcome, while secondary outcomes included biomarkers, haemostasis indices, safety events, and Sequential Organ Failure Assessment (SOFA) score at 24 h after surgery.

Six patients who completed follow-up were included in the final analysis. Removal rates differed, ranging from ‒79.4 percent to 18.6 percent (mean ‒15.8 percent, median 4.0 percent). Interleukin-6, -8, and -10 reached peak levels at 6 h and declined by 24‒48 h after surgery. The highest temperature was 37.6 °C, and organ dysfunction was mild (SOFA score 3.83). [Sci Rep 2026;16:31171]

With regard to adverse events (AEs), acute kidney injury occurred in one patient. Stroke, respiratory failure, major cardiovascular or cerebrovascular events, or device-related AEs were not reported.

“[O]ur novel adsorption system did not consistently reduce numbers of circulating CD11b⁺ neutrophils. Instead, it slightly reduced numbers in some and strongly increased numbers in others during surgery, after which the numbers rose in all patients,” the researchers said.

“The adsorption system minimally affected numbers of other leukocytes and of erythrocytes, and it did not trigger coagulation dysfunction or inflammation to any clinical extent,” they added.

Adsorber system

An earlier study of the same adsorption system within a CPB circuit through which human blood flowed ex vivo found minimal effects on red blood cells and platelets but demonstrated promising removal of CD11b⁺ neutrophils and other activated leukocytes. [J Inflamm Res 2025;18:5355-5370]

“Our present results with the six patients suggest that removal by the adsorber system may not outpace the replacement of adsorbed leukocytes by new ones that mobilize into the circulation or that become activated during surgery,” the researchers said.

In other pilot studies of different leukocyte adsorbers, net increases in activation markers were likewise observed despite membrane-based removal. [J Thorac Cardiovasc Surg 2005;129:851-859]

“Leukocyte activation during CPB is multifactorial, and clinical CPB also introduces additional stimuli largely absent from simplified ex vivo circuits, arising from cardiotomy suction and the venous reservoir,” according to the researchers. [Eur J Cardiothorac Surg 2002;21:232-244; Anesth Analg 1997;85:766-782]

An in-vitro cardiotomy-suction model showed air exposure increasing granulocyte CD11b expression in a previous study, while another found leukocyte filtration of cardiotomy suction blood did not result in decreased upregulation of CD11b during CPB. [Perfusion 2018;33:538-545; Perfusion 2017;32:574-582]

“Taken together, ongoing activation can mask any net decrease achieved by adsorptive removal,” the researchers said. “The findings from our two pilot studies imply that our peptide-coated membrane can selectively adsorb leukocytes without reducing counts of other white blood cells, in contrast to other reported membranes.” [J Thorac Cardiovasc Surg 2002;123:218-224]

“Efficacy and safety of leukocyte removal should be assessed in larger samples, preferably with a parallel control arm,” they said.